Key facts
- It has raised $43.1M; the latest was Early Stage VC ($27.9M) in Aug 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Zhengxuan Investment, Leading Capital Company, Sichuan Yizhan Capital Management, Huangshan Industrial Investment Group — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Yixi Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Yixi Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yixi Biotechnology
Manufacturer of synthetic biology-based food and health solutions aims to advance innovative biomanufacturing and expand the boundaries of human food sources. The company's offerings feature multiple R&D pipelines with a focus on food additives, a pioneering human milk oligosaccharide (HMO) biosynthesis project that has achieved domestic industrialization, and ongoing exploration of foundational synthetic biology technologies, enabling the creation of sustainable, high-value ingredients while deepening insights into the logic of life and driving technological breakthroughs in biomanufacturing.
- Sector
- Business Products and Services (B2B)
- HQ
- Suzhou, China
- Founded
- 2019
- Employees
- 7
- Website
- yixilife.com/
- Ownership
- Privately Held (backing)
Yixi Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yixi Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yixi Biotechnology in its N-PORT filings yet. We sweep new filings monthly.